EDIT

Editas Medicine Stock Price

39.31
-0.15 (-0.38%)
Upgrade to Real-Time
Afterhours (Closed)
39.31
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Editas Medicine Inc EDIT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.15 -0.38% 39.31 19:58:57
Open Price Low Price High Price Close Price Prev Close
40.69 38.25 40.69 39.51 39.46
Bid Price Ask Price Spread News
39.01 39.51 0.50 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
18,272 1,095,744 $ 39.73 $ 43,529,887 3,902,301 21.41 - 99.95
Last Trade Time Type Quantity Stock Price Currency
19:58:24 1 $ 39.03 USD

Editas Medicine Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.47B 62.87M 62.81M $ 20.53M $ -13.84M -2.68 -38.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Editas Medicine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EDIT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week44.5145.43138.2541.291,071,373-5.20-11.68%
1 Month46.3549.1737.1443.181,542,610-7.04-15.19%
3 Months74.0076.899936.1053.342,425,226-34.69-46.88%
6 Months33.6099.9527.1257.672,245,7085.7116.99%
1 Year22.0699.9521.4149.311,590,05717.2578.2%
3 Years34.8999.9514.0137.981,078,8284.4212.67%
5 Years37.4899.9512.4333.90964,7421.834.88%

Editas Medicine Description

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.


Your Recent History
NASDAQ
EDIT
Editas Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.